HITA: An Architecture for System-level Testing of Healthcare IoT Applications

System-level testing of healthcare Internet of Things (IoT_ applications requires creating a test infrastructure with integrated medical devices and third-party applications. A significant challenge in creating such test infrastructure is that healthcare IoT applications evolve continuously with the addition of new medical devices from different vendors and new services offered by different third-party organizations following different architectures. Moreover, creating test infrastructure with a large number of different types of medical devices is time-consuming, financially expensive, and practically infeasible. Oslo City healthcare department faced these challenges while working with various healthcare IoT applications. This paper presents a real-world software architecture (HITA) to create a test infrastructure for healthcare IoT applications. We discuss the quality requirements achieved by HITA and the status of work products developing as a part of HITA. We also present our experiences and lessons learned from the architectural work related to HITA.Comment: To appear in the Proceedings of the 17th European Conference on Software Architecture (ECSA 2023

Testing Real-World Healthcare IoT Application: Experiences and Lessons Learned

Healthcare Internet of Things (IoT) applications require rigorous testing to ensure their dependability. Such applications are typically integrated with various third-party healthcare applications and medical devices through REST APIs. This integrated network of healthcare IoT applications leads to REST APIs with complicated and interdependent structures, thus creating a major challenge for automated system-level testing. We report an industrial evaluation of a state-of-the-art REST APIs testing approach (RESTest) on a real-world healthcare IoT application. We analyze the effectiveness of RESTest's testing strategies regarding REST APIs failures, faults in the application, and REST API coverage, by experimenting with six REST APIs of 41 API endpoints of the healthcare IoT application. Results show that several failures are discovered in different REST APIs with ~56% coverage using RESTest. Moreover, nine potential faults are identified. Using the evidence collected from the experiments, we provide our experiences and lessons learned.Comment: To appear in the Proceedings of the 31st ACM Joint European Software Engineering Conference and Symposium on the Foundations of Software Engineering (ESEC/FSE 2023

Phytoremediation of Heavy Metals: An Indispensable Contrivance in Green Remediation Technology

Environmental contamination is triggered by various anthropogenic activities, such as using pesticides, toxic chemicals, industrial effluents, and metals. Pollution not only affects both lotic and lentic environments but also terrestrial habitats, substantially endangering plants, animals, and human wellbeing. The traditional techniques used to eradicate the pollutants from soil and water are considered expensive, environmentally harmful and, typically, inefficacious. Thus, to abate the detrimental consequences of heavy metals, phytoremediation is one of the sustainable options for pollution remediation. The process involved is simple, effective, and economically efficient with large-scale extensive applicability. This green technology and its byproducts have several other essential utilities. Phytoremediation, in principle, utilizes solar energy and has an extraordinary perspective for abating and assembling heavy metals. The technique of phytoremediation has developed in contemporary times as an efficient method and its success depends on plant species selection. Here in this synthesis, we are presenting a scoping review of phytoremediation, its basic principles, techniques, and potential anticipated prospects. Furthermore, a detailed overview pertaining to biochemical aspects, progression of genetic engineering, and the exertion of macrophytes in phytoremediation has been provided. Such a promising technique is economically effective as well as eco-friendly, decontaminating and remediating the pollutants from the biosphere

Delivery of siRNAs against MERS-CoV in Vero and HEK-293 cells: A comparative evaluation of transfection reagents

Background: A new coronavirus was identified in Jeddah, Saudi Arabia in 2012 and designated as Middle East Respiratory Syndrome Coronavirus (MERS-CoV). To date, this virus has been reported in 27 countries. The virus transmission to humans has already been reported from camels. Currently, there is no vaccine or antiviral therapy available against this virus. Methods: The siRNAs were in silico predicted, designed, and chemically synthesized by using the MERS-CoV-orf1ab region as a target. The antiviral activity was experimentally evaluated by delivering the siRNAs with Lipofectamine™ 2000 and JetPRIMER as transfection reagents in both Vero cell and HEK-293-T cell lines at two different concentrations (10.0 nM and 5.0 nM). The Ct value of quantitative Real-Time PCR (qRT-PCR) was used to calculate and determine the reduction of viral RNA level in both cell supernatant and cell lysate isolated from both cell lines. Results: The sequence alignment resulted in the selection of highly conserved regions. The orf1ab region was used to predict and design the siRNAs and a total of twenty-one siRNAs were finally selected from four hundred and twenty-six siRNAs generated by online software. Inhibition of viral replication and significant reduction of viral RNA was observed against selected siRNAs in both cell lines at both concentrations. Based on the Ct value, the siRNAs # 11, 12, 18, and 20 were observed to be the best performing in both cell lines at both concentrations. Conclusion: Based on the results and data analysis, it is concluded that the use of two different transfection reagents was significantly effective. But the Lipofectamine™ 2000 was found to be a better transfection reagent than the JetPRIMER for the delivery of siRNAs in both cell lines

Molecular Docking of Bacterial Protein Modulators and Pharmacotherapeutics of <i>Carica papaya</i> Leaves as a Promising Therapy for Sepsis: Synchronising In Silico and In Vitro Studies

Sepsis is a serious health concern globally, which necessitates understanding the root cause of infection for the prevention of proliferation inside the host’s body. Phytochemicals present in plants exhibit antibacterial and anti-proliferative properties stipulated for sepsis treatment. The aim of the study was to determine the potential role of Carica papaya leaf extract for sepsis treatment in silico and in vitro. We selected two phytochemical compounds, carpaine and quercetin, and docked them with bacterial proteins, heat shock protein (PDB ID: 4PO2), surfactant protein D (PDB ID: 1PW9), and lactobacillus bacterial protein (PDB ID: 4MKS) against imipenem and cyclophosphamide. Quercetin showed the strongest interaction with 1PW9 and 4MKS proteins. The leaves were extracted using ethanol, methanol, and water through Soxhlet extraction. Total flavonoid content, DPPH assay, HPTLC, and FTIR were performed. In vitro cytotoxicity of ethanol extract was screened via MTT assay on the J774 cell line. Ethanol extract (EE) possessed the maximum number of phytocomponents, the highest amount of flavonoid content, and the maximum antioxidant activity compared to other extracts. FTIR analysis confirmed the presence of N-H, O-H, C-H, C=O, C=C, and C-Cl functional groups in ethanol extract. Cell viability was highest (100%) at 25 µg/mL of EE. The present study demonstrated that the papaya leaves possessed antibacterial and cytotoxic activity against sepsis infection

Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 and causes severe and often fatal acute respiratory illness in humans. No approved prophylactic and therapeutic interventions are currently available. In this study, we have developed egg yolk antibodies (immunoglobulin Y (IgY)) specific for MERS-CoV spike protein (S1) in order to evaluate their neutralizing efficiency against MERS-CoV infection. S1-specific immunoglobulins were produced by injecting chickens with purified recombinant S1 protein of MERS-CoV at a high titer (5.7 mg/mL egg yolk) at week 7 post immunization. Western blotting and immune-dot blot assays demonstrated that the IgY antibody specifically bound to the MERS-CoV S1 protein. Anti-S1 antibodies were also able to recognize MERS-COV inside cells, as demonstrated by an immunofluorescence assay. Plaque reduction and microneutralization assays showed the neutralization of MERS-COV in Vero cells by anti-S1 IgY antibodies and non-significantly reduced virus titers in the lungs of MERS-CoV-infected mice during early infection, with a nonsignificant decrease in weight loss. However, a statistically significant (p = 0.0196) quantitative reduction in viral antigen expression and marked reduction in inflammation were observed in lung tissue. Collectively, our data suggest that the anti-MERS-CoV S1 IgY could serve as a potential candidate for the passive treatment of MERS-CoV infection